Literature DB >> 11290814

Anergy induction by dimeric TCR ligands.

H Appel1, N P Seth, L Gauthier, K W Wucherpfennig.   

Abstract

T cells that recognize particular self Ags are thought to be important in the pathogenesis of autoimmune diseases. In multiple sclerosis, susceptibility is associated with HLA-DR2, which can present myelin-derived peptides to CD4(+) T cells. To generate molecules that target such T cells based on the specificity of their TCR, we expressed a soluble dimeric DR2-IgG fusion protein with a bound peptide from myelin basic protein (MBP). Soluble, dimeric DR2/MBP peptide complexes activated MBP-specific T cells in the absence of signals from costimulatory or adhesion molecules. This initial signaling through the TCR rendered the T cells unresponsive (anergic) to subsequent activation by peptide-pulsed APCs. Fluorescent labeling demonstrated that anergic T cells were initially viable, but became susceptible to late apoptosis due to insufficient production of cytokines. Dimerization of the TCR with bivalent MHC class II/peptide complexes therefore allows the induction of anergy in human CD4(+) T cells with a defined MHC/peptide specificity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290814      PMCID: PMC3414419          DOI: 10.4049/jimmunol.166.8.5279

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.

Authors:  Y Li; X C Li; X X Zheng; A D Wells; L A Turka; T B Strom
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

Authors:  A D Wells; X C Li; Y Li; M C Walsh; X X Zheng; Z Wu; G Nuñez; A Tang; M Sayegh; W W Hancock; T B Strom; L A Turka
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

3.  Multivalent structure of an alphabetaT cell receptor.

Authors:  G Fernández-Miguel; B Alarcón; A Iglesias; H Bluethmann; M Alvarez-Mon; E Sanz; A de la Hera
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

Review 4.  The role of MHC class II molecules in susceptibility and resistance to autoimmunity.

Authors:  H O McDevitt
Journal:  Curr Opin Immunol       Date:  1998-12       Impact factor: 7.486

5.  A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.

Authors:  L S Madsen; E C Andersson; L Jansson; M krogsgaard; C B Andersen; J Engberg; J L Strominger; A Svejgaard; J P Hjorth; R Holmdahl; K W Wucherpfennig; L Fugger
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

6.  Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells.

Authors:  H Appel; L Gauthier; J Pyrdol; K W Wucherpfennig
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

7.  Determination of lymphocyte division by flow cytometry.

Authors:  A B Lyons; C R Parish
Journal:  J Immunol Methods       Date:  1994-05-02       Impact factor: 2.303

8.  Erythropoietin receptor activation by a ligand-induced conformation change.

Authors:  I Remy; I A Wilson; S W Michnick
Journal:  Science       Date:  1999-02-12       Impact factor: 47.728

9.  Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation.

Authors:  O Livnah; E A Stura; S A Middleton; D L Johnson; L K Jolliffe; I A Wilson
Journal:  Science       Date:  1999-02-12       Impact factor: 47.728

10.  The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.

Authors:  H Arentz-Hansen; R Körner; O Molberg; H Quarsten; W Vader; Y M Kooy; K E Lundin; F Koning; P Roepstorff; L M Sollid; S N McAdam
Journal:  J Exp Med       Date:  2000-02-21       Impact factor: 14.307

View more
  15 in total

Review 1.  Immunopathogenesis of multiple sclerosis: MBP and beyond.

Authors:  E Meinl; R Hohlfeld
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

2.  Engineered Materials for Cancer Immunotherapy.

Authors:  Alexander S Cheung; David J Mooney
Journal:  Nano Today       Date:  2015-08-01       Impact factor: 20.722

Review 3.  Targeting T lymphocytes for immune monitoring and intervention in autoimmune diabetes.

Authors:  Roberto Mallone; Gerald T Nepom
Journal:  Am J Ther       Date:  2005 Nov-Dec       Impact factor: 2.688

Review 4.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

5.  Functional avidity directs T-cell fate in autoreactive CD4+ T cells.

Authors:  Roberto Mallone; Sharon A Kochik; Helena Reijonen; Bryan Carson; Steven F Ziegler; William W Kwok; Gerald T Nepom
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

Review 6.  Peptide-MHC-based nanovaccines for the treatment of autoimmunity: a "one size fits all" approach?

Authors:  Xavier Clemente-Casares; Sue Tsai; Yang Yang; Pere Santamaria
Journal:  J Mol Med (Berl)       Date:  2011-04-16       Impact factor: 4.599

Review 7.  Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.

Authors:  Chunsong Yu; Jingchao Xi; Meng Li; Myunggi An; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-12-06       Impact factor: 4.774

8.  Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8+ T cells.

Authors:  Dibyendu Samanta; Gayatri Mukherjee; Udupi A Ramagopal; Rodolfo J Chaparro; Stanley G Nathenson; Teresa P DiLorenzo; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

9.  Suppression of ongoing T cell-mediated autoimmunity by peptide-MHC class II dimer vaccination.

Authors:  Li Li; Zuoan Yi; Bo Wang; Roland Tisch
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

10.  MHC class II derived recombinant T cell receptor ligands protect DBA/1LacJ mice from collagen-induced arthritis.

Authors:  Jianya Huan; Laurie J Kaler; Jeffery L Mooney; Sandhya Subramanian; Corwyn Hopke; Arthur A Vandenbark; Edward F Rosloniec; Gregory G Burrows; Halina Offner
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.